about
Site-specific functionalization of proteins and their applications to therapeutic antibodiesSupercritical carbon dioxide design strategies: from drug carriers to soft killersGlycosylation of therapeutic proteins: an effective strategy to optimize efficacyVaginal delivery of the recombinant HIV-1 clade-C trimeric gp140 envelope protein CN54gp140 within novel rheologically structured vehicles elicits specific immune responsesGlycosylation, an effective synthetic strategy to improve the bioavailability of therapeutic peptides.Laser-engineered dissolving microneedle arrays for transdermal macromolecular drug delivery.Next generation delivery system for proteins and genes of therapeutic purpose: why and how?Chemical glycosylation of cytochrome c improves physical and chemical protein stability.Activation of caspase-dependent apoptosis by intracellular delivery of Cytochrome c-based nanoparticles.Low viscosity highly concentrated injectable nonaqueous suspensions of lysozyme microparticles.Protein modification with amphiphilic block copoly(2-oxazoline)s as a new platform for enhanced cellular delivery.Modulating protein release profiles by incorporating hyaluronic acid into PLGA microparticles Via a spray dryer equipped with a 3-fluid nozzle.Integration of drug, protein, and gene delivery systems with regenerative medicine.The targeted intracellular delivery of cytochrome C protein to tumors using lipid-apolipoprotein nanoparticles.Neurogenic Effects of Cell-Free Extracts of Adipose Stem Cells.Silylated precision particles for controlled release of proteins.Noninvasive delivery technologies: respiratory delivery of vaccines.Poly(2-oxazoline)s as polymer therapeutics.Protein engineering strategies for sustained glucagon-like peptide-1 receptor-dependent control of glucose homeostasis.Pharmacokinetics of recombinant bifunctional fusion proteins.Effects of glycosylation on the stability of protein pharmaceuticals.Peptide/protein vaccine delivery system based on PLGA particles.The long-term potential of biodegradable poly(lactide-co-glycolide) microparticles as the next-generation vaccine adjuvant.Peptide delivery using phospholipid micelles.Nanocarriers targeting dendritic cells for pulmonary vaccine delivery.Ceramic nanocarriers: versatile nanosystem for protein and peptide delivery.Critical challenges to the design of drug-eluting medical devices.Peptide pills for brain diseases? Reality and future perspectives.Strategies for enhanced peptide and protein delivery.Pharmacokinetics and pharmacokinetic-pharmacodynamic correlations of therapeutic peptides.Injectable controlled release depots for large molecules.Formulation strategies to improve oral peptide delivery.Enhancing the buccal mucosal delivery of peptide and protein therapeutics.Materials and methods for delivery of biological drugs.Combining Stimulus-Triggered Release and Active Targeting Strategies Improves Cytotoxicity of Cytochrome c Nanoparticles in Tumor Cells.Technosphere insulin: defining the role of Technosphere particles at the cellular level.Comment on: "A Single Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of Orally Administered Des-aspartate Angiotensin I in Healthy Subjects".Implementation of mixture design for formulation of albumin containing enteric-coated spray-dried microparticles.High-capacity functional protein encapsulation in nanoengineered polypeptide microcapsules.Strategies and industrial perspectives to improve oral absorption of biological macromolecules.
P2860
Q26830699-C6854808-A660-4A5A-8937-4B65E6B65B6DQ28085090-EE506F97-8612-4639-9131-48A6E5CA2DFEQ33586660-1A93D68B-D5F2-45AA-BEF2-15C5A1599531Q33665816-FA45362E-9F11-4BEB-9B24-ED16545FF808Q33814126-C944C13E-88E2-4974-887F-FF6EA2C21163Q33856010-CD2635C1-18EE-4697-9722-BB26E870261EQ34003800-ACA3B3E7-93EA-4724-8A90-5B218EEACC75Q34062756-C1616B70-9C63-49F8-9240-7C5F154DE4D9Q34544795-2CCC36AD-7C68-4869-B9F3-3C7E34F1AFE3Q34581175-60B1B9A5-12EE-457C-8B0F-779C38D45BDDQ34761834-7BCF8FB7-3BF1-4CD9-A284-4F4A628612AFQ35175078-968096A5-9CEA-4A13-915F-E0A39554401EQ35241569-91CDA21B-C465-493B-8480-C693E883F4ADQ35840461-CB950860-98D5-4787-BE3F-D39AF64C242BQ35918069-0F302AC1-6FB0-4591-BCB6-7334276E2417Q35983600-39691C81-5625-43DA-8242-9B858B03E463Q36349694-02C7DDC3-DB55-470F-8F7D-A77E2EE1BF5EQ36716915-F33A818F-32D5-4B86-87DB-7BBE221DD096Q36756501-AE49D6F9-C2C6-48B8-AE2D-7C8EB34B49C6Q37033032-8A79E1D1-515F-4EA6-AE43-3CB2ED43E3C3Q37114305-98AE3FBB-3127-4087-A797-1D57182F52C2Q37838652-872FF2C1-7BFC-411C-A8DD-119A388596BEQ37956385-E83E7FC0-44D7-4785-AB59-BA210686D8A7Q38030889-9167CD92-D1C8-4EB1-958F-E7A8BAC56E60Q38051096-1E478159-E808-475E-8D3B-76AED35EFE82Q38069606-1D805235-3751-4438-9640-710C3AE0D3B9Q38096035-877BB4C6-BF22-43A9-9437-A7EA0F178A0FQ38096036-A285D9C7-3949-4FB2-B915-32022058506BQ38104408-077069F3-5BB6-45D6-891C-F2F839AA0BD5Q38110433-E40D7239-6C95-4656-98A4-922A062B3B0AQ38220192-44707A52-080C-407C-A0F3-745CB169A095Q38226675-3347B17C-75BC-45D9-B609-A423F232F76BQ38244323-0DC7119D-6F28-4779-9F18-D500C571745CQ38987392-BB17597D-2013-4373-BF42-EB6111DDC145Q39694741-D679AA59-34A2-4CD9-93AB-BD3196074452Q39741788-9FD0B8A5-CC92-459F-9D05-EB366949ADE5Q42320631-46C23155-DB52-4EEC-ABE1-08C9369467ADQ45890488-BCAC8F9A-8CB6-4DDF-B1B4-1C54D50ABB4BQ46863720-6E097174-750F-4351-AB04-6490D44E88F0Q47431381-BD35763B-C4FA-4B54-BF33-17D609BB84D2
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Commercial challenges of protein drug delivery.
@ast
Commercial challenges of protein drug delivery.
@en
type
label
Commercial challenges of protein drug delivery.
@ast
Commercial challenges of protein drug delivery.
@en
prefLabel
Commercial challenges of protein drug delivery.
@ast
Commercial challenges of protein drug delivery.
@en
P2860
P356
P1476
Commercial challenges of protein drug delivery.
@en
P2093
Larry R Brown
P2860
P356
10.1517/17425247.2.1.29
P407
P577
2005-01-01T00:00:00Z